The spectrum of statin myopathy

Payam Mohassel, Andrew L. Mammen

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: This review discusses the spectrum of myopathies associated with statin use, with special attention given to a recently identified statin-associated autoimmune-necrotizing myopathy. The clinical characteristics of these patients, pathologic findings, associated autoantibody and immunogenetic risk factors are discussed. RECENT FINDINGS: In the past several years, a novel form of autoimmunemyopathy associated with statin use has been described. Patients with this form of myositis have unique clinical, pathologic and pathophysiologic features when compared with those with self-limited statin toxic myopathy. An autoantibody directed against HMG-CoA reductase (HMGCR), the pharmacologic target of statins, characterizes the disease and can be used in clinical practice to identify these patients and direct therapy. Still, many questions remain to be answered regarding the pathogenic mechanisms at play, risk factors for developing the disease, long-term prognosis and effects of rechallenge with statins or other cholesterol-lowering drugs. SUMMARY: Statins can cause a spectrum of muscle diseases, most of which are self-limited and improve with discontinuation of the offending agent. In a subgroup, an autoimmune necrotizing myopathy develops that persists after discontinuation of statins. Specific autoantibody testing can help identify these patients in clinical practice and determine the need for immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)747-752
Number of pages6
JournalCurrent Opinion in Rheumatology
Volume25
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Autoantibodies
Hydroxymethylglutaryl CoA Reductases
Immunogenetics
Myositis
Poisons
Immunosuppressive Agents
Cholesterol
Muscles
Therapeutics

Keywords

  • Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody
  • Autoantibodies
  • Autoimmune
  • Muscle
  • Myopathy
  • Myositis
  • Statin

ASJC Scopus subject areas

  • Rheumatology

Cite this

The spectrum of statin myopathy. / Mohassel, Payam; Mammen, Andrew L.

In: Current Opinion in Rheumatology, Vol. 25, No. 6, 11.2013, p. 747-752.

Research output: Contribution to journalArticle

Mohassel, Payam ; Mammen, Andrew L. / The spectrum of statin myopathy. In: Current Opinion in Rheumatology. 2013 ; Vol. 25, No. 6. pp. 747-752.
@article{fd1840d7fbd24ca8855b16bea66bc9b2,
title = "The spectrum of statin myopathy",
abstract = "PURPOSE OF REVIEW: This review discusses the spectrum of myopathies associated with statin use, with special attention given to a recently identified statin-associated autoimmune-necrotizing myopathy. The clinical characteristics of these patients, pathologic findings, associated autoantibody and immunogenetic risk factors are discussed. RECENT FINDINGS: In the past several years, a novel form of autoimmunemyopathy associated with statin use has been described. Patients with this form of myositis have unique clinical, pathologic and pathophysiologic features when compared with those with self-limited statin toxic myopathy. An autoantibody directed against HMG-CoA reductase (HMGCR), the pharmacologic target of statins, characterizes the disease and can be used in clinical practice to identify these patients and direct therapy. Still, many questions remain to be answered regarding the pathogenic mechanisms at play, risk factors for developing the disease, long-term prognosis and effects of rechallenge with statins or other cholesterol-lowering drugs. SUMMARY: Statins can cause a spectrum of muscle diseases, most of which are self-limited and improve with discontinuation of the offending agent. In a subgroup, an autoimmune necrotizing myopathy develops that persists after discontinuation of statins. Specific autoantibody testing can help identify these patients in clinical practice and determine the need for immunosuppressive therapy.",
keywords = "Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody, Autoantibodies, Autoimmune, Muscle, Myopathy, Myositis, Statin",
author = "Payam Mohassel and Mammen, {Andrew L.}",
year = "2013",
month = "11",
doi = "10.1097/01.bor.0000434673.85515.89",
language = "English (US)",
volume = "25",
pages = "747--752",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The spectrum of statin myopathy

AU - Mohassel, Payam

AU - Mammen, Andrew L.

PY - 2013/11

Y1 - 2013/11

N2 - PURPOSE OF REVIEW: This review discusses the spectrum of myopathies associated with statin use, with special attention given to a recently identified statin-associated autoimmune-necrotizing myopathy. The clinical characteristics of these patients, pathologic findings, associated autoantibody and immunogenetic risk factors are discussed. RECENT FINDINGS: In the past several years, a novel form of autoimmunemyopathy associated with statin use has been described. Patients with this form of myositis have unique clinical, pathologic and pathophysiologic features when compared with those with self-limited statin toxic myopathy. An autoantibody directed against HMG-CoA reductase (HMGCR), the pharmacologic target of statins, characterizes the disease and can be used in clinical practice to identify these patients and direct therapy. Still, many questions remain to be answered regarding the pathogenic mechanisms at play, risk factors for developing the disease, long-term prognosis and effects of rechallenge with statins or other cholesterol-lowering drugs. SUMMARY: Statins can cause a spectrum of muscle diseases, most of which are self-limited and improve with discontinuation of the offending agent. In a subgroup, an autoimmune necrotizing myopathy develops that persists after discontinuation of statins. Specific autoantibody testing can help identify these patients in clinical practice and determine the need for immunosuppressive therapy.

AB - PURPOSE OF REVIEW: This review discusses the spectrum of myopathies associated with statin use, with special attention given to a recently identified statin-associated autoimmune-necrotizing myopathy. The clinical characteristics of these patients, pathologic findings, associated autoantibody and immunogenetic risk factors are discussed. RECENT FINDINGS: In the past several years, a novel form of autoimmunemyopathy associated with statin use has been described. Patients with this form of myositis have unique clinical, pathologic and pathophysiologic features when compared with those with self-limited statin toxic myopathy. An autoantibody directed against HMG-CoA reductase (HMGCR), the pharmacologic target of statins, characterizes the disease and can be used in clinical practice to identify these patients and direct therapy. Still, many questions remain to be answered regarding the pathogenic mechanisms at play, risk factors for developing the disease, long-term prognosis and effects of rechallenge with statins or other cholesterol-lowering drugs. SUMMARY: Statins can cause a spectrum of muscle diseases, most of which are self-limited and improve with discontinuation of the offending agent. In a subgroup, an autoimmune necrotizing myopathy develops that persists after discontinuation of statins. Specific autoantibody testing can help identify these patients in clinical practice and determine the need for immunosuppressive therapy.

KW - Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody

KW - Autoantibodies

KW - Autoimmune

KW - Muscle

KW - Myopathy

KW - Myositis

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84885296961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885296961&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000434673.85515.89

DO - 10.1097/01.bor.0000434673.85515.89

M3 - Article

C2 - 24061077

AN - SCOPUS:84885296961

VL - 25

SP - 747

EP - 752

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -